US FDA Commissioner: The Waiting Game Continues
Executive Summary
The wait for a permanent head of the FDA is continuing into the second year of the Biden Administration. One message is coming through loud and clear: the agency is clearly not a top priority for the White House ... and that might just be a good thing.
You may also be interested in...
The Labors Of Califf
The US FDA Commissioner nominee Robert Califf has so far promised to revamp FDA’s opioids policy, stay away from industry after leaving the agency, and clean up Accelerated Approval in 30 days. What other tasks will Democratic Senators demand before granting him confirmation?
Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation
Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.
FDA’s Awkward Transition Continues
US FDA’s apolitical leadership team is highly unusual – but is it a strength or a weakness in a new Administration? Acting Commissioner Janet Woodcock has been running the agency for nearly six months and there are no signs of the status quo changing any time soon.